Federal health regulators say the toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh the drug's benefits for patients with a type of blood cancer.
The Food and Drug Administration warned that patients taking the drug carfilzomib in company studies had a high rate of heart and lung side effects, some which were fatal. The FDA posted its review
of the drug ahead of a Wednesday meeting of its cancer drugs panel.
Onyx has asked the FDA to approve carfilzomib as a treatment for patients with advanced forms of multiple myeloma whose disease has
spread despite treatment with other drugs.
Onyx shares fell almost 5 percent in premarket trading.
Multiple myeloma affects plasma cells in bone marrow. Over 50,000 people have the disease in the U.S., and about 20,000 new
cases are diagnosed every year.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.